Please use this identifier to cite or link to this item:
Title: Glutamate Transporter Glt1 Expression In Alzheimer Disease And Dementia With Lewy Bodies
Author: Garcia Esparcia, Paula
Diaz-Lucena, Daniela
Ainciburu, Marina
Torrejón-Escribano, Benjamín
Carmona Murillo, Margarita
Llorens Torres, Franc
Ferrer, Isidro (Ferrer Abizanda)
Keywords: Malaltia d'Alzheimer
Àcid glutàmic
Transport biològic
Alzheimer's disease
Glutamic acid
Biological transport
Issue Date: 26-Apr-2018
Publisher: Frontiers Media Sa
Abstract: Glutamate transporter solute carrier family 1, member 2 (GLT1/EAAT2), a major modulator of glutamate homeostasis in astrocytes, is assessed in post-mortem human brain samples of frontal cortex area 8 in advanced stages of Alzheimer disease (AD) and terminal stages of dementia with Lewy bodies (DLB) in order to gain understanding of astrogliopathy in diseases manifested by dementia. Glial fibrillary acidic protein (GFAP) mRNA expression is significantly increased in AD but not in DLB, whereas GLT1, vesicular glutamate transporter 1 (vGLUT1) and aldehyde dehydrogenase 1 family member 1 (ALDH1L1) are not modified in AD and DLB when compared with controls. GLT1 protein levels are not altered in AD and DLB but GFAP and ALDH1L1 are significantly increased in AD, and GFAP in DLB. As a result, a non-significant decrease in the ratio between GLT1 and GFAP, and between GLT1 and ALDH1L1, is found in both AD and DLB. Double-labeling immunofluorescence and confocal microscopy revealed no visible reduction of GLT1 immunoreactivity in relation to beta-amyloid plaques in AD. These data suggest a subtle imbalance between GLT1, and GFAP and ALDH1L1 expression, with limited consequences in glutamate transport.
Note: Reproducció del document publicat a:
It is part of: Frontiers In Aging Neuroscience, 2018, Vol. 10, Article 122
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
Garcia-EsparciaP.pdf1.95 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons